Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Accumulated Expenses (2024 - 2025)

Historic Other Accumulated Expenses for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $963000.0.

  • Prelude Therapeutics' Other Accumulated Expenses rose 2022.47% to $963000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $963000.0, marking a year-over-year increase of 2022.47%. This contributed to the annual value of $771000.0 for FY2024, which is N/A changed from last year.
  • Per Prelude Therapeutics' latest filing, its Other Accumulated Expenses stood at $963000.0 for Q3 2025, which was up 2022.47% from $861000.0 recorded in Q2 2025.
  • Prelude Therapeutics' Other Accumulated Expenses' 5-year high stood at $963000.0 during Q3 2025, with a 5-year trough of $455000.0 in Q2 2024.